CompanyBMRNNasdaqNovato, CA

Biomarin Pharmaceutical Inc

BioMarin develops therapies for genetically defined rare diseases.

SEC EDGAR ClinicalTrials.gov

8-KSep 30Latest SEC filing

Sep 30Latest story

September 2026

BioMarin and Ascendis sign settlement and license agreement over CNP patents

Sep 30PartnershipBiomarin Pharmaceutical Inc

August 2026

BioMarin and Ascendis settle global patent dispute over Yuviwel

Aug 31PartnershipAscendis Pharma A/S Biomarin Pharmaceutical Inc

BioMarin to acquire Alesta Therapeutics for its oral HPP drug candidate ALE1

Aug 18M&ABiomarin Pharmaceutical Inc

BioMarin raises 2026 revenue and VOXZOGO guidance, discontinues BMN 401

Aug 6Quarterly updateBiomarin Pharmaceutical Inc vosoritide

July 2026

Amicus reports FY2025 results as BioMarin merger deal proceeds

Jul 13PeopleBiomarin Pharmaceutical Inc